MicroRNAs as novel therapeutic targets against inflammatory bowel disease through modulation of ferroptosis

Area of Science:

• Gastroenterology
• Molecular Biology
• Cell Death Research

Background:

• Inflammatory Bowel Disease (IBD) involves chronic gut inflammation and barrier dysfunction.
• Ferroptosis, an iron-dependent cell death, critically damages intestinal epithelium in IBD.
• MicroRNAs (miRNAs) are key regulators of ferroptosis, impacting IBD pathogenesis.

Purpose of the Study:

• To review the role of the miRNA-ferroptosis network in IBD.
• To explore how dysregulated miRNAs contribute to intestinal epithelial injury.
• To examine novel miRNA-based therapeutic strategies for IBD.

Main Methods:

• Literature review synthesizing evidence on miRNAs, ferroptosis, and IBD.
• Analysis of specific miRNA dysregulation (e.g., miR-129-5p, IRF7/miR-375 axis) in IBD.
• Examination of emerging therapeutic interventions targeting ferroptosis.

Main Results:

• Dysregulated miRNAs promote ferroptosis by impairing antioxidant defenses and lipid metabolism.
• Specific miRNAs like miR-129-5p and the IRF7/miR-375 axis are implicated in epithelial damage.
• Novel therapies like ABX464 and exosome systems show promise for IBD treatment.

Conclusions:

• The miRNA-ferroptosis axis is a critical factor in IBD pathogenesis.
• Targeting ferroptosis via miRNA modulation offers a novel therapeutic avenue.
• MiRNA-based interventions represent a promising strategy for mucosal healing in IBD, potentially overcoming resistance to biologics.